189 related articles for article (PubMed ID: 25600908)
21. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
Karthik S; Sankar R; Varunkumar K; Ravikumar V
Biomed Pharmacother; 2014 Apr; 68(3):327-34. PubMed ID: 24485799
[TBL] [Abstract][Full Text] [Related]
22. Proteomics-based identification of secreted protein dihydrodiol dehydrogenase 2 as a potential biomarker for predicting cisplatin efficacy in advanced NSCLC patients.
Kuang P; Zhou C; Li X; Ren S; Li B; Wang Y; Li J; Tang L; Zhang J; Zhao Y
Lung Cancer; 2012 Aug; 77(2):427-32. PubMed ID: 22534668
[TBL] [Abstract][Full Text] [Related]
23. XIAP-mediated protection of H460 lung cancer cells against cisplatin.
Cheng YJ; Jiang HS; Hsu SL; Lin LC; Wu CL; Ghanta VK; Hsueh CM
Eur J Pharmacol; 2010 Feb; 627(1-3):75-84. PubMed ID: 19903469
[TBL] [Abstract][Full Text] [Related]
24. Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression.
Wu DW; Wu TC; Wu JY; Cheng YW; Chen YC; Lee MC; Chen CY; Lee H
Oncogene; 2014 Aug; 33(35):4385-95. PubMed ID: 24096476
[TBL] [Abstract][Full Text] [Related]
25. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer.
Ceppi P; Mudduluru G; Kumarswamy R; Rapa I; Scagliotti GV; Papotti M; Allgayer H
Mol Cancer Res; 2010 Sep; 8(9):1207-16. PubMed ID: 20696752
[TBL] [Abstract][Full Text] [Related]
26. Role of 14-3-3σ in resistance to cisplatin in non-small cell lung cancer cells.
Cetintas VB; Tetik A; Cok G; Kucukaslan AS; Kosova B; Gunduz C; Veral A; Eroglu Z
Cell Biol Int; 2013 Jan; 37(1):78-86. PubMed ID: 23339090
[TBL] [Abstract][Full Text] [Related]
27. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
28. Enhanced antitumor effect of cisplatin in human NSCLC cells by tumor suppressor LKB1.
Ou W; Ye S; Yang W; Wang Y; Ma Q; Yu C; Shi H; Yuan Z; Zhong G; Ren J; Zhu W; Wei Y
Cancer Gene Ther; 2012 Jul; 19(7):489-98. PubMed ID: 22576699
[TBL] [Abstract][Full Text] [Related]
29. (-)-Epigallocatechin-3-gallate inhibits human papillomavirus (HPV)-16 oncoprotein-induced angiogenesis in non-small cell lung cancer cells by targeting HIF-1α.
He L; Zhang E; Shi J; Li X; Zhou K; Zhang Q; Le AD; Tang X
Cancer Chemother Pharmacol; 2013 Mar; 71(3):713-25. PubMed ID: 23292117
[TBL] [Abstract][Full Text] [Related]
30. The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin.
Li P; Wang K; Zhang J; Zhao L; Liang H; Shao C; Sutherland LC
Cancer Epidemiol; 2012 Oct; 36(5):481-9. PubMed ID: 22609235
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and evaluation of N-hydroxypropenamides based on adamantane to overcome resistance in NSCLC.
Bao X; Sun Y; Bao C; Zhang J; Zou S; Yang J; Wu C; Wang L; Chen G
Bioorg Chem; 2019 May; 86():696-704. PubMed ID: 30831531
[TBL] [Abstract][Full Text] [Related]
32. Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death.
Rundall BK; Denlinger CE; Jones DR
Surgery; 2004 Aug; 136(2):416-25. PubMed ID: 15300209
[TBL] [Abstract][Full Text] [Related]
33. Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer.
Wang W; Zhao M; Cui L; Ren Y; Zhang J; Chen J; Jia L; Zhang J; Yang J; Chen G; Ashby CR; Wu C; Chen ZS; Wang L
Mol Cancer; 2020 Sep; 19(1):134. PubMed ID: 32878625
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic therapy potential of suberoylanilide hydroxamic acid on invasive human non-small cell lung cancer cells.
Zhang S; Wu K; Feng J; Wu Z; Deng Q; Guo C; Xia B; Zhang J; Huang H; Zhu L; Zhang K; Shen B; Chen X; Ma S
Oncotarget; 2016 Oct; 7(42):68768-68780. PubMed ID: 27634890
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer.
Xu L; Huang Y; Chen D; He J; Zhu W; Zhang Y; Liu X
Cancer Genet; 2014 May; 207(5):214-20. PubMed ID: 24906642
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin-induced downregulation of SOX1 increases drug resistance by activating autophagy in non-small cell lung cancer cell.
Li N; Li X; Li S; Zhou S; Zhou Q
Biochem Biophys Res Commun; 2013 Sep; 439(2):187-90. PubMed ID: 23994634
[TBL] [Abstract][Full Text] [Related]
37. Arctigenin enhances chemosensitivity to cisplatin in human nonsmall lung cancer H460 cells through downregulation of survivin expression.
Wang HQ; Jin JJ; Wang J
J Biochem Mol Toxicol; 2014 Jan; 28(1):39-45. PubMed ID: 24395429
[TBL] [Abstract][Full Text] [Related]
38. IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules.
Duan S; Tsai Y; Keng P; Chen Y; Lee SO; Chen Y
Oncotarget; 2015 Sep; 6(29):27651-60. PubMed ID: 26313152
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.
Wang L; Liu X; Ren Y; Zhang J; Chen J; Zhou W; Guo W; Wang X; Chen H; Li M; Yuan X; Zhang X; Yang J; Wu C
Cell Death Dis; 2017 Apr; 8(4):e2746. PubMed ID: 28406482
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells.
Weng SH; Tseng SC; Huang YC; Chen HJ; Lin YW
Biochem Pharmacol; 2012 Jul; 84(1):126-36. PubMed ID: 22480737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
